Cargando…

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies

OBJECTIVE: To estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population. METHODS: We conducted a pooled analysis of cohort studies on COVID-19 in patients with MS published until July 31, 2021. We calculated the pooled crude deat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prosperini, Luca, Tortorella, Carla, Haggiag, Shalom, Ruggieri, Serena, Galgani, Simonetta, Gasperini, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446478/ https://www.ncbi.nlm.nih.gov/pubmed/34533590 http://dx.doi.org/10.1007/s00415-021-10803-3

Ejemplares similares

Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
por: Prosperini, Luca, et al.
Publicado: (2022)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2014)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

The added value of spinal cord lesions to disability accrual in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2023)

Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis
por: Corsetti, Marta, et al.
Publicado: (2019)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis
por: Kunkl, Martina, et al.
Publicado: (2019)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
por: Gasperini, Claudio, et al.
Publicado: (2012)

Lesion symptom map of cognitive–postural interference in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2017)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems
por: Bargagli, Anna Maria, et al.
Publicado: (2016)

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
por: Pozzilli, Carlo, et al.
Publicado: (2021)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Predicting the profile of increasing disability in multiple sclerosis
por: Tomassini, Valentina, et al.
Publicado: (2018)

Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients
por: Capone, Alessia, et al.
Publicado: (2019)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

Spotlight on postural control in patients with multiple sclerosis
por: Prosperini, Luca, et al.
Publicado: (2018)

“Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study
por: Calabrese, Massimiliano, et al.
Publicado: (2019)

Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis
por: Angelini, Daniela F., et al.
Publicado: (2013)

Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis
por: Amadio, Susanna, et al.
Publicado: (2017)

The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review
por: Prosperini, Luca, et al.
Publicado: (2013)

Identifying responders and nonresponders to interferon therapy in multiple sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis
por: Sambucci, Manolo, et al.
Publicado: (2018)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients
por: Dalla Libera, Dacia, et al.
Publicado: (2011)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
por: Prosperini, Luca, et al.
Publicado: (2011)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients
por: Di Bari, Maria, et al.
Publicado: (2016)

Functional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2015)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments
por: Pietrolongo, Erika, et al.
Publicado: (2013)

Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation
por: Reale, Marcella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0lsk8r071l2gk2g93j997dbc49